TapewireFind a company

person · Reporting owner

Schulz Marcus

Disclosed activity across 1 company

Tapewire entity
110156
SEC CIK
0001812702

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOLIFE SOLUTIONS INCBLFS · Entity 4614Chief Revenue OfficerAugust 25, 2023August 29, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOLIFE SOLUTIONS INC

Report date August 25, 2023 · Filed August 29, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect42,097 Reported balance After 2023-08-25 transaction · row 1
1 source row

Row 1 · 2023-08-25 · Sale · Disposed 347 · Balance 42,097

F1: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 25, 2023 Filed Aug 29, 2023 21:54 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 347 $10.99 $3,813.53
Disclosure

SEC source: 0001628280-23-030917 · wk-form4_1693346070.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,097

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:49 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 108 $12.38 $1,337.04
Disclosure

SEC source: 0001628280-23-029687 · wk-form4_1692218936.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,444

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:09 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 679 $19.50 $13,240.50
Disclosure

SEC source: 0001628280-23-025784 · wk-form4_1690409364.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,552

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 07-17-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 11, 2023 Filed Jul 13, 2023 21:10 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 331 $22.79 $7,543.49
Disclosure

SEC source: 0001628280-23-024862 · wk-form4_1689282625.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,231

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-07-2019 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 337 $23.21 $7,821.77
Disclosure

SEC source: 0001437749-23-016544 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,562

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 15, 2023 Filed May 18, 2023 01:53 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 75 $18.71 $1,403.25
Disclosure

SEC source: 0001437749-23-015005 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,899

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 19, 2023 Filed Apr 21, 2023 23:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 430 $19.33 $8,311.90
Disclosure

SEC source: 0001437749-23-010842 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,062

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 7/17/2020

Read SEC document
April 14, 2023 Filed Apr 18, 2023 23:28 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 215 $21.05 $4,525.75
Disclosure

SEC source: 0001437749-23-010569 · primary_doc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,492

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 06, 2023 Filed Apr 10, 2023 23:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 771 $20.03 $15,443.13
Disclosure

SEC source: 0001437749-23-009875 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,707

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 06, 2023 Filed May 17, 2023 01:48 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 771 $20.03 $15,443.13
Disclosure

SEC source: 0001437749-23-014862 · rdgdoc.xml · nonDerivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,619

F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,912 shares.

Read SEC document
March 31, 2023 Filed May 17, 2023 01:48 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionRestricted Stock Award · Derivative 2,912 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-23-014862 · rdgdoc.xml · derivative · entry 3

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,912 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
March 31, 2023 Filed May 17, 2023 01:48 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Exercise / conversionCommon Stock 2,912 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-23-014862 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,390

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 903 $22.75 $20,543.25
Disclosure

SEC source: 0001437749-23-005442 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,478

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
February 09, 2023 Filed Feb 14, 2023 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 56 $24.60 $1,377.60
Disclosure

SEC source: 0001437749-23-003206 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,381

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 23, 2023 Filed Jan 26, 2023 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 1,000 $25.02 $25,020.00
Disclosure

SEC source: 0001437749-23-001797 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,437

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $25.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 19, 2023 Filed Jan 21, 2023 00:23 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 538 $22.93 $12,336.34
Disclosure

SEC source: 0001437749-23-001484 · rdgdoc.xml · nonDerivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,437

F3 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 18, 2023 Filed Jan 21, 2023 00:23 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 3,000 $25.04 $75,120.00
Disclosure

SEC source: 0001437749-23-001484 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,975

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.10, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 11, 2023 Filed Jan 13, 2023 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 258 $21.94 $5,660.52
Disclosure

SEC source: 0001437749-23-000970 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,975

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 03, 2023 Filed Jan 11, 2023 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 12,733 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-23-000818 · rdgdoc.xml · derivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,733

Underlying: Common Stock · 12,733 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

Read SEC document
January 03, 2023 Filed Jan 11, 2023 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 12,733 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-23-000818 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,233

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.

Read SEC document
November 10, 2022 Filed Nov 15, 2022 01:06 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 40 $23.16 $926.40
Disclosure

SEC source: 0001437749-22-027398 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,500

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 28, 2022 Filed Nov 1, 2022 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 400 $21.76 $8,704.00
Disclosure

SEC source: 0001437749-22-025240 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,540

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 14, 2022 Filed Oct 19, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 236 $21.80 $5,144.80
Disclosure

SEC source: 0001437749-22-024345 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,940

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
August 10, 2022 Filed Aug 12, 2022 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 42 $23.17 $973.14
Disclosure

SEC source: 0001437749-22-020215 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,176

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
August 03, 2022 Filed Aug 6, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 4,600 $20.03 $92,138.00
Disclosure

SEC source: 0001437749-22-019237 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,218

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of June 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.06, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 22, 2022 Filed Jul 27, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 367 $17.94 $6,583.98
Disclosure

SEC source: 0001437749-22-017813 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,818

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 12, 2022 Filed Jul 15, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 254 $15.79 $4,010.66
Disclosure

SEC source: 0001437749-22-017162 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,185

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 13, 2022 Filed May 18, 2022 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 41 $12.32 $505.12
Disclosure

SEC source: 0001437749-22-012846 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,439

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 21, 2022 Filed Apr 23, 2022 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 477 $13.94 $6,649.38
Disclosure

SEC source: 0001437749-22-009566 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,480

F1 · kind: The sale reported herein was made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 18, 2022 Filed Apr 20, 2022 00:15 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 286 $17.59 $5,030.74
Disclosure

SEC source: 0001437749-22-009259 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,957

F1 · date: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59.

F1 · kind: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59.

F1 · price: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59.

Read SEC document
February 24, 2022 Filed Mar 10, 2022 02:20 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 14,019 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-22-005771 · rdgdoc.xml · derivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,019

Underlying: Common Stock · 14,019 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

Read SEC document
February 24, 2022 Filed Mar 10, 2022 02:20 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 14,019 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-22-005771 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,243

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation.

Read SEC document
February 10, 2022 Filed Feb 15, 2022 01:03 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 167 $29.38 $4,906.46
Disclosure

SEC source: 0001437749-22-003347 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,224

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 20, 2022 Filed Jan 25, 2022 02:07 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 395 $30.24 $11,944.80
Disclosure

SEC source: 0001437749-22-001523 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,391

F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 12, 2022 Filed Jan 14, 2022 01:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 267 $32.18 $8,592.06
Disclosure

SEC source: 0001437749-22-000889 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,786

F1 · shares: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
November 09, 2021 Filed Nov 13, 2021 01:21 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 1,750 $53.00 $92,750.00
Disclosure

SEC source: 0001437749-21-026560 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,053

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of August 19, 2021.

Read SEC document
October 20, 2021 Filed Oct 23, 2021 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 399 $42.34 $16,893.66
Disclosure

SEC source: 0001437749-21-024188 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,803

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 11, 2021 Filed Oct 14, 2021 00:09 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 245 $38.22 $9,363.90
Disclosure

SEC source: 0001437749-21-023621 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,202

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 26, 2021 Filed Jul 29, 2021 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 650 $46.78 $30,407.00
Disclosure

SEC source: 0001437749-21-017792 · rdgdoc.xml · nonDerivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,447

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

Read SEC document
July 26, 2021 Filed Jul 29, 2021 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 4,269 $45.48 $194,154.12
Disclosure

SEC source: 0001437749-21-017792 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,097

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $46.42, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 20, 2021 Filed Jul 23, 2021 00:31 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,539 $45.10 $114,508.90
Disclosure

SEC source: 0001437749-21-017395 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,366

F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 08, 2021 Filed Jul 10, 2021 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 140 $45.72 $6,400.80
Disclosure

SEC source: 0001437749-21-016741 · rdgdoc.xml · nonDerivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,905

F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 08, 2021 Filed Jul 10, 2021 00:00 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 100 $45.75 $4,575.00
Disclosure

SEC source: 0001437749-21-016741 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,045

F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 20, 2021 Filed Apr 22, 2021 00:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 650 $32.10 $20,865.00
Disclosure

SEC source: 0001437749-21-009507 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,145

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

Read SEC document
April 08, 2021 Filed Apr 13, 2021 01:31 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 224 $35.77 $8,012.48
Disclosure

SEC source: 0001437749-21-008758 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,795

F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.75 to $35.78, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
February 12, 2021 Filed Mar 6, 2021 01:01 UTC Amendment BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,000 $41.01 $82,020.00
Disclosure

SEC source: 0001437749-21-005202 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,107

F1 · security: This Form 4/A is being filed to amend the Form 4 originally filed by the reporting person on February 16, 2021 solely to correct the transaction date in Column 2 on Table I. No other changes have been made to the original Form 4.

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

Read SEC document
February 08, 2021 Filed Feb 20, 2021 01:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantRestricted Stock Award · Derivative 2,912 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001437749-21-003515 · rdgdoc.xml · derivative · entry 2

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,912

Underlying: Common Stock · 2,912 shares

Expires not disclosed

F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.

Read SEC document
February 08, 2021 Filed Feb 20, 2021 01:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 2,912 Not disclosed Not disclosed
Disclosure

SEC source: 0001437749-21-003515 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,019

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation.

Read SEC document
January 12, 2021 Filed Feb 17, 2021 01:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,000 $41.01 $82,020.00
Disclosure

SEC source: 0001437749-21-003035 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,107

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.

Read SEC document
January 08, 2021 Filed Jan 14, 2021 01:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 293 $39.01 $11,429.93
Disclosure

SEC source: 0001437749-21-000683 · rdgdoc.xml · nonDerivative · entry 1

Schulz Marcus · CIK 0001812702 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,107

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.